APX3330 inhibits NFκB and HIF-1α activity [31], and can potentially attenuate neuroinflammatory responses and post ischemic angiogenesis, which makes APX3330 a suitable candidate for stroke therapy in DM rats. This evidence concerns the gene NFKB1 and stroke disorder.